460 related articles for article (PubMed ID: 33735191)
1. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
2. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
3. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.
Erstad DJ; Sojoodi M; Taylor MS; Jordan VC; Farrar CT; Axtell AL; Rotile NJ; Jones C; Graham-O'Regan KA; Ferreira DS; Michelakos T; Kontos F; Chawla A; Li S; Ghoshal S; Chen YI; Arora G; Humblet V; Deshpande V; Qadan M; Bardeesy N; Ferrone CR; Lanuti M; Tanabe KK; Caravan P; Fuchs BC
Clin Cancer Res; 2020 Sep; 26(18):5007-5018. PubMed ID: 32611647
[TBL] [Abstract][Full Text] [Related]
4. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis.
van Erning FN; Mackay TM; van der Geest LGM; Groot Koerkamp B; van Laarhoven HWM; Bonsing BA; Wilmink JW; van Santvoort HC; de Vos-Geelen J; van Eijck CHJ; Busch OR; Lemmens VE; Besselink MG;
Acta Oncol; 2018 Dec; 57(12):1655-1662. PubMed ID: 30264642
[TBL] [Abstract][Full Text] [Related]
5. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
6. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
7. The impact of resection margin distance on survival and recurrence in pancreatic ductal adenocarcinoma in a retrospective cohort analysis.
Obonyo D; Uslar VN; Münding J; Weyhe D; Tannapfel A
PLoS One; 2023; 18(2):e0281921. PubMed ID: 36800357
[TBL] [Abstract][Full Text] [Related]
8. Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions.
Pine JK; Haugk B; Robinson SM; Darne A; Wilson C; Sen G; French JJ; White SA; Manas DM; Charnley RM
Pancreatology; 2020 Apr; 20(3):537-544. PubMed ID: 31996296
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
10. The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy.
Watson MD; Thompson KJ; Musselwhite LW; Hwang JJ; Baker EH; Martinie JB; Vrochides D; Iannitti DA; Ocuin LM
Am J Surg; 2021 Jul; 222(1):159-166. PubMed ID: 33121658
[TBL] [Abstract][Full Text] [Related]
11. Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis.
Teske C; Stimpel R; Distler M; Merkel S; Grützmann R; Bolm L; Wellner U; Keck T; Aust DE; Weitz J; Welsch T
Langenbecks Arch Surg; 2021 Aug; 406(5):1481-1489. PubMed ID: 33712875
[TBL] [Abstract][Full Text] [Related]
12. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.
Depypere L; Moons J; Lerut T; De Hertogh G; Peters C; Sagaert X; Coosemans W; Van Veer H; Nafteux P
Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036407
[TBL] [Abstract][Full Text] [Related]
14. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
[TBL] [Abstract][Full Text] [Related]
15. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Cecchini M; Miccio JA; Pahade J; Lacy J; Salem RR; Johnson SB; Blakaj A; Stein S; Kortmansky JS; Johung KL
Pancreas; 2020 Aug; 49(7):904-911. PubMed ID: 32658074
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Ghaneh P; Kleeff J; Halloran CM; Raraty M; Jackson R; Melling J; Jones O; Palmer DH; Cox TF; Smith CJ; O'Reilly DA; Izbicki JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Padbury R; Shannon J; Dervenis C; Glimelius B; Deakin M; Anthoney A; Lerch MM; Mayerle J; Oláh A; Rawcliffe CL; Campbell F; Strobel O; Büchler MW; Neoptolemos JP;
Ann Surg; 2019 Mar; 269(3):520-529. PubMed ID: 29068800
[TBL] [Abstract][Full Text] [Related]
17. Is it time to stop checking frozen section neck margins during pancreaticoduodenectomy?
Lad NL; Squires MH; Maithel SK; Fisher SB; Mehta VV; Cardona K; Russell MC; Staley CA; Adsay NV; Kooby DA
Ann Surg Oncol; 2013 Oct; 20(11):3626-33. PubMed ID: 23838908
[TBL] [Abstract][Full Text] [Related]
18. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.
Herman JM; Swartz MJ; Hsu CC; Winter J; Pawlik TM; Sugar E; Robinson R; Laheru DA; Jaffee E; Hruban RH; Campbell KA; Wolfgang CL; Asrari F; Donehower R; Hidalgo M; Diaz LA; Yeo C; Cameron JL; Schulick RD; Abrams R
J Clin Oncol; 2008 Jul; 26(21):3503-10. PubMed ID: 18640931
[TBL] [Abstract][Full Text] [Related]
19. Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
Panaro F; Kellil T; Vendrell J; Sega V; Souche R; Piardi T; Leon P; Cassinotto C; Assenat E; Rosso E; Navarro F
J Surg Oncol; 2019 Sep; 120(3):483-493. PubMed ID: 31197842
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study.
Delpero JR; Jeune F; Bachellier P; Regenet N; Le Treut YP; Paye F; Carrere N; Sauvanet A; Adham M; Autret A; Poizat F; Turrini O; Boher JM
Ann Surg; 2017 Nov; 266(5):787-796. PubMed ID: 28953554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
